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Abstract
Background: Cervical intraepithelial neoplasia (CIN) grades 2 and 3 are usually grouped and treated in the same
way as “high grade”, in spite of their different risk to cancer progression and spontaneous regression rates. CIN2-3
is usually diagnosed in formaldehyde-fixed paraffin embedded (FFPE) punch biopsies. This procedure virtually
eliminates the availability of water-soluble proteins which could have diagnostic and prognostic value.
Aim: To investigate whether a water-soluble protein-saving biopsy processing method followed by a proteomic
analysis of supernatant samples using LC-MS/MS (LTQ Orbitrap) can be used to distinguish between CIN2 and CIN3.
Methods: Fresh cervical punch biopsies from 20 women were incubated in RPMI1640 medium for 24 hours at 4°C
for protein extraction and subsequently subjected to standard FFPE processing. P16 and Ki67-supported histologic
consensus review CIN grade (CIN2, n = 10, CIN3, n = 10) was assessed by independent gynecological pathologists.
The biopsy supernatants were depleted of 7 high abundance proteins prior to uni-dimensional LC-MS/MS analysis
for protein identifications.
Results: The age of the patients ranged from 25-40 years (median 29.7), and mean protein concentration was 0.81
mg/ml (range 0.55 - 1.14). After application of multistep identification criteria, 114 proteins were identified, including
proteins like vimentin, actin, transthyretin, apolipoprotein A-1, Heat Shock protein beta 1, vitamin D binding protein
and different cytokeratins. The identified proteins are annotated to metabolic processes (36%), signal transduction
(27%), cell cycle processes (15%) and trafficking/transport (9%). Using binary logistic regression, Cytokeratin 2 was
found to have the strongest independent discriminatory power resulting in 90% overall correct classification.
Conclusions: 114 proteins were identified in supernatants from fresh cervical biopsies and many differed between
CIN2 and 3. Cytokeratin 2 is the strongest discriminator with 90% overall correct classifications.
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Background
Among female cancers, cervical cancer has the second
highest occurrence worldwide with an incidence in 2002
of 493,000 women (20% in developed countries and 80%
in developing countries), with 274,000 estimated deaths
[1]. High-risk Human Papilloma Virus genotypes are the
most important risk factors for development of cervical
cancer after infection of cervical epithelial cells [2].
Non-invasive cervical intraepithelial neoplasias (CIN)
precede the development of invasive cancer and is much
more frequent as the estimated risk for progression of a
CIN2-3 lesion is less than 10%, furthermore the progres-
sion from CIN to (micro)invasive cancer can take 10-25
years [3]. Three grades are used by The World Health
Organization to distinguish the degree of epithelial
abnormality (CIN1, CIN2 and CIN3). These grades are
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development, but CIN grades are not static events. A
CIN lesion is a dynamic process that can progress to
cancer, persist as the same CIN grade but also regress
[4]. If left untreated, 5-30% of all histologically con-
firmed CIN2-3 lesions will over time develop invasive
cancer [5]. Consequently all punch-biopsy confirmed
CIN2-3 lesions are usually treated with diathermic cone
excision [6]. This is a relatively aggressive therapy
because up to 40% of CIN2-3 lesions will regress spon-
taneously without cone excision [7]. Cone excision may
induce side effects, including cervical insufficiency,
w h i c hi sas e r i o u sl a t ec o m p l i c a t i o n[ 8 , 9 ] .T h i sm a y
require hospitalization and immobilization of women
with later pregnancy, from 16 weeks gestation. As the age
of becoming pregnant rises, and the median detection
age of CIN2-3 is 29 years only, the clinical importance of
cervical insufficiency as a side effect increases. It is there-
fore of paramount importance to identify CIN2-3 lesions
which could safely be treated with less aggressive therapy
than cone excision, and find new diagnostic and prognos-
tic predictive methods that can predict those CIN2-3
lesions that will regress spontaneously.
The distinction of a CIN2 lesion from a CIN3 lesion
can be challenging. In addition, CIN2 lesions regress to a
higher degree than CIN3 lesions, so an improvement in
the diagnostic accuracy of high grade CIN’s can poten-
tially reduce the number of over treated patients [4].
Functional biomarkers like Ki67, pRb, p53 and cyto-
keratin 13/14 have proven to be helpful in predicting
regression or not [4]. The type of immune-reactive cells
in the microenvironment of a CIN lesion is also predic-
tive for regression. One of the challenges is that the
local immune response induced by the HPV-infection
must be detected in formalin-fixed paraffin embedded
(FFPE) tissue [10], which is used worldwide for the his-
topathological diagnosis of cervical lesions. The FFPE
procedure virtually eliminates the availability of water-
soluble proteins which could have diagnostic and prog-
nostic value. Aggregated information provided by such
biomarkers exceeds the value of the grading system.
Establishment of new biomarkers to support prediction
of regression or not may result in even more accurate
CIN treatment [11].
Several studies have been performed using different
sample collection and analysis technologies for different
samples such as cervicovaginal washings [12,13], cervical
mucus [14] and cells supernatant from cytobrush collec-
tion [15]. A protein collection method for small punch
biopsy samples that could represent not only the cellular
response but also water soluble proteins from the cervi-
cal neoplasia microenvironment may further help to
define the biological dynamic behavior of CIN lesions.
We have previously shown that a panel of 3 peaks from
SELDI-TOF protein profiles can be used to differentiate
normal tissue from CIN tissue samples [16] utilizing a
method resembling the one published by Celis et al
[17]. However, SELDI-TOF has certain shortcomings,
and the aim of the present pilot study therefore was to
compare CIN2 and CIN3 samples from this protein-sav-
ing biopsy processing method using shotgun proteomics
[18]. We utilized nanoflow liquid chromatography
coupled to a LTQ-Orbitrap mass spectrometer to iden-
tify proteins from the biopsies or the microenvironment
to the neoplasia within the biopsies. At the same time,
the tissue was preserved for conventional microscopic
and immunohistochemical studies.
Methods
Study population
This study is a sub-project from a larger prospective
observational study, approved by the Regional Medical
Ethics Committee of Helse Vest, Norway, the Norwe-
gian Data Inspection, and the Health Directorate of
Norway, #33.06, #17185 and #07/330. In this observa-
tional study, healthy women aged 25-40 years, with
cytologically abnormal smears were followed by cervical
biopsy and later cone excision. In total, 254 patients
with first time onset of CIN have been included from
January 2007 to December 2008. The interval between
punch biopsy and cone excision was standardized at
median 113 days (range: 100-126). Ninety-five percent
of the patients had an interval between 87 and 139 days.
All patients included in this study were treated accord-
ing to the national Norwegian population screening
quality guidelines [19]. Of the 254 patients with cervical
punch biopsy samples, a random subset of 10 diagnosed
as CIN2 and 10 diagnosed as CIN3 were selected for
the current pilot study. The samples were selected so
that the whole sampling period was covered and the
protein concentration was as close to the average for
the whole data set as possible. The age and punch-cone
excision interval of these 20 patients was not different
from the whole group.
Sample collection
After colposcopy, punch biopsies and endocervical cur-
ettage were taken from the transformation zone and
eventually premalignant mucosal changes, and stored in
4% buffered formaldehyde, 1-2 additional biopsies were
immediately placed in polystyrene tubes (Sarsted, Nurm-
brecht, Germany) containing 5 ml RPMI 1640 (Gibco,
Carlsbad, USA) tissue culture medium and kept there
for 24 hours at 4°C. After this period, the supernatants
were collected, split into aliquots of 500 μl and stored at
-80°C until analysis.
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As described before [16], after 24 hours incubation in
RPMI1640 medium the biopsies were routinely fixed in
buffered 4% formaldehyde, embedded in paraffin, cut at
4 μm, and stained with hematoxylin, eosin and safran
(HES) for routine histological examination. P16 and
MIB-1 immunohistochemical (IHC) stainings were used
to confirm the diagnosis. All HES and IHC sections of
the 254 biopsies were reviewed by two independent
pathologists also using the p16 and MIB-1 immunohis-
tochemical information, but who otherwise were blinded
to the original routine clinical findings, histopathological
diagnosis and follow-up. In case of discrepancies the
cases were re-reviewed and diagnosed on a double-head
microscope by two pathologists (EG, JB) and a consen-
sus diagnosis was always obtained. The cases used for
this study were diagnosed as follows: CIN2 (n = 10) and
CIN3 (n = 10).
Immunohistochemistry
Paraffin sections were mounted onto Superfrost Plus
slides (Menzel, Braunschweig, Germany) and dried over-
night at 37°C followed by 1 h at 60°C. Sections were
deparaffinized in xylene and rehydrated in decreasing
concentrations of alcohol. Antigen was retrieved with a
highly stabilized retrieval system (ImmunoPrep, Instru-
mec, Oslo, Norway) using 10 mM TRIS/1 mM EDTA
(pH 9.0) as the retrieval buffer. Sections were heated for
3 min at 110°C followed by 10 min at 95°C and cooled
to 20°C.
Mouse monoclonal Cytokeratin 2e clone Ks2.342.7.1
(Abcam, Cambridge, UK,) were used. The primary anti-
body was used at a 1:25 dilution in Dako antibody dilu-
ent (S0809). The EnVisionTMFlex+ detection system
(Dako, Glostrup, Denmark, K8002) were used for visua-
lization. Sections were incubated for 5 min. with peroxy-
dase-blocking reagent (SM801), 30 min. with the
primary antibody, 20 min. with the EnVision™ FLEX+
Mouse Linker (SM804), 20 min. with the EnVision™
FLEX/HRP Detection Reagent (SM802), 10 min. with
EnVision™ FLEX DAB+ Chromogen (DM827)/EnVi-
sion™ FLEX Substrate Buffer (SM803) mix and 5 min.
with EnVision™ FLEX Hematoxylin (K8008). The slides
were dehydrated and mounted. Immunohistochemical
stainings were performed using a Dako Autostainer Link
48 instrument and EnVision™ FLEX Wash Buffer
(DM831).
Immunoaffinity depletion
The preparation of the immunoaffinity column is
described in Additional file 1. To deplete samples of the
7 high-abundance proteins, 100 μl of RPMI supernatant
was diluted with 100 μl tris-buffered saline (TBS, 0.1 M
TRIS-base containing 0.1 M NaCl, pH 8.0), and the
solution was injected into a TBS solution with a flow of
0.2 ml/min. The non-retained proteins were trapped on
a 4 mm × 2.0 mm id. C18 Security Guard Cartridge with
300Å pore size (Phenomenex, Torrance, CA, USA), and
were eluted by backflushing the security guard cartridge
with ethanol at a flow of 0.3 ml/min. The affinity col-
umn was washed using 0.1 M glycine at pH 2.5 with a
flow of 1.2 ml/min. Both columns were re-equilibrated
with TBS at a flow of 0.2 ml/min for 5 minutes. The pH
adjustments were done using 6 M HCl.
Protein digestion and sample cleanup
After evaporating the ethanol-phase containing the non-
retained protein fraction using vacuum-centrifugation
(Eppendorf Concentrator 5301, VWR, Norway), 100 μl
50 mM ammonium-bicarbonate pH 8 was added to the
samples. 1 μl of 1 M dithiothreitol (DTT) was added to
reduce the proteins. 5 μl of 1 M iodoacetamide (IAA)
was then added to alkylate the proteins followed by 5 μl
of DTT to stop the alkylation process. For each of these
steps, 45 minute incubation time was used. One μg tryp-
sin (Promega) was added, and the samples were kept at
37°C for 18 hours. After trypsination, the samples were
purified and concentrated using a C18 ZipTip (Millipore,
Norway) procedure. The ZipTips were conditioned by
aspiring 30 μl acetonitrile five times and equilibrated
with pulling 30 μl 0.1% formic acid (FA) in MilliQ water
five times through the stationary phase. Approximately
10 μl of the 0.1% FA solution was left above the station-
ary phase to avoid drying it. Each sample solution was
applied on top of the stationary phase using a pipette,
and then pushed through the tip using air pressure from
the pipette plunger. More sample solution was added
when approximately 20 μl of the liquid remained so that
the whole volumes of the samples were pushed slowly
through the ZipTip. Washing was done by aspiring 30
μl of 0.1% FA five times. Elution of the peptides was
done in a total volume of 30 μl of 80:20 (v/v) acetoni-
trile:MilliQ water by aspiring 10 μl of this solution 10
times through the stationary phase. The organic phase
was then evaporated using vacuum-centrifugation and
to the residual solution, 20 μl 0.1% FA was added prior
to the LC-MS/MS analysis.
LC-MS/MS analysis
A Dionex Ultimate 3000 nanoflow HPLC equipped with
a3 0 0μm i.d × 0.5 cm length Acclaim PepMap 100 C18
trap column and a 75 μm id. × 15 cm Acclaim PepMap
100 C18 analytical column (Dionex) were used with a
LTQ-Orbitrap hybrid mass spectrometer (Thermo
Scientific). 5 μl of the tryptic digests were injected onto
the trap column using 0.1% formic acid (FA, VWR) in
MilliQ-water (Elga) at a flow of 2 μl/min. The separa-
tion was done using a gradient from 2.5% to 64%
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min flow. A 10 minute post-injection delay and a 20
minute column re-equilibration time were used. The
electrospray interface was a PicoTip emitter (SilicaTip,
New Objective) with a 10 μmt i pw i t h o u tc o a t i n g .T h e
electrospray voltage was set to 1 kV. No sheath gas was
used. The mass spectrometer was used in positive mode.
Full scans were performed in the Orbitrap using the m/z
range from 200 to 2000. Data dependent MS/MS scans
were performed in the LTQ for the five most abundance
masses with z ≥2 and intensity higher than 10000
counts. Dynamic exclusion for 3 minutes after fragmen-
tation of a given m/z value four times was used. Colli-
sion induced dissociation (CID) was used with a
collision energy of 35%, activation Q setting of 0.400
and 30 ms activation time for MS. Calibration of the
mass spectrometer was done weekly using the calibra-
tion solution recommended by Thermo Scientific.
Data analysis
The raw data files were analyzed using the Proteome
Discoverer 1.0 (Thermo Scientific) with the Sequest
algorithm to search against the Homo Sapiens (Tax.id:
9606) database at NCBI (531420 sequences) with trypsin
as digestion enzyme allowing for 2 missed cleavages. All
files were also searched against the Human Papilloma
Virus database (Tax.id: 10566) at NCBI (1615
sequences). Precursor ion tolerance was set to 10 ppm,
and fragment ion mass tolerance to 0.8 Da. Oxidation
(M) was set as a dynamic modification and carbamido-
methyl (C) was set as a static modification due to the
use of DTT and IAA. A high significance peptide confi-
dence filter was set in Proteome Discoverer (PD) from
Thermo, which means that peptide identifications are
filtered based on the following combination of charge
and Xcorr factor: 1.9 (z = 2), 2.3 (z = 3) and 2.6 (z≥4).
The InforSense plugin to Proteome Discoverer was used
to collect gene ontology (GO) data. Information of other
relevant biological processes for each protein was
obtained from the Amigo database (http://amigo.gen-
eontology.org).
To enable identification of proteins with low molecu-
lar weights that can result in one or only a few tryptic
peptides, protein identifications were accepted using one
peptide under certain conditions: The sequest Xcorr fac-
tor with regards to charge had to be fulfilled according
to the high significance criteria in PD. The peptide had
to contain at least 7 amino acids, and at least three con-
secutive b- and y-ions had to be present in the spectra
[20], and it should be found minimum three times in
the same sample. In addition, for proteins with only one
identified peptide sequence, the peptide sequence were
submitted to a BLAST search against the Uniprot
Homo Sapiens database (http://www.uniprot.org) to
confirm that the identification matched the NCBI iden-
tification. The identification process is described in
figure 1. For proteins listed as Unnamed in the NCBI
database, the ID mapping tool at UniProt was used to
see if the protein was listed with a more descriptive
annotation in this database.
Spectral count (SPC) results for the identified peptides
were obtained and used for normalization (equation 1)
after increasing all numbers with 1 to avoid zeros.
SPC NormProtein x,Sample x,Group y = SPCProtein x, Sample x ×
Sum SPCSample x
Avg.SPCGroupy
The normalized SPC results were then imported into
SPSS (v17, SPSS, Oslo, Norway) for statistical calcula-
tions using descriptive statistics and for developing a
Figure 1 Flow chart for the acceptance process for protein
identification using one peptide.
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method. A Classification and Regression Tree analysis
was done using CART (Salford, San Diego, CA, USA).
Results
The median age of the patients at the time that the
biopsies were obtained was 29.7 years (range 25-40),
and the mean protein concentration of the selected sam-
ples, measured by Bradford, was 0.81 mg/ml (range 0.55
- 1.14). The samples were subjected to depletion of 7
high abundance proteins followed by tryptic digestion
and uni-dimensional LC-MS/MS analysis. Using the
high-significance peptide confidence filter in Proteome
Discoverer, peptides from a total of 193 protein entries
were identified. Applying the identification criteria for
proteins with only one peptide, a total of 114 protein
identifications were included (table 1). Thirty six of
these were identified with two or more unique peptides
and the rest with only one unique peptide. Peptides
from Human Papilloma Virus proteins were detected in
all samples, but not with high enough confidence to
give acceptable protein identifications. Albumin, haemo-
globins and immunoglobulins were excluded from the
protein list in table S1 in Additional file 2 despite that
they fulfilled the protein identification criteria.
Figure 2 show a gene ontology (GO) bar diagram for
the biological processes covered by the proteins in the
CIN2 and CIN3 groups identified by Proteome
Discoverer.
T h eI n f o r S e n s em o d u l ec o u l da s s i g nG Op r o c e s s e st o
46 (53%) and 60 (53%) of the identified proteins in the
CIN2 and CIN3 group, respectively. Among these 46
and 60 proteins with assigned GO process, the most fre-
quent occurring processes are signal transduction with
16 proteins in both groups, which is 35% of the proteins
in the CIN2 group and 27% of the proteins in the CIN3
group. Proteins related to cell cycle were represented by
4p r o t e i n si nt h eC I N 2g r o u p( 9 % )a n d9i nt h eC I N 3
group (15%). In total, 15 (33%) and 20 (33%) of the pro-
teins with a GO annotation are involved in metabolic
processes in the CIN2 and CIN3 groups respectively. In
the CIN3 group, proteins involved in energy metabolism
(2) and inorganic ion transport and metabolism (2) were
identified as well.
Several of the identified proteins are related to other
biological processes than is shown in figure 2, and was
obtained from Amigo (figure 3). Proteins involved in
immune responses are heat shock protein beta-1, apoli-
poprotein A-I, alpha-1-acid glycoprotein 1, dermcidin,
macrophage migration inhibitory factor and cystatin-C.
Other proteins have been shown to be involved in host-
virus interactions or virus response mechanisms, for
example high motility group protein AT-hook protein 1,
hemopexin, apolipoprotein A-II, keratins 8 and 19, Heat
shock protein beta-1 and vimentin.
The classification results obtained by developing a bin-
ary logistic regression model based on the normalized
spectral counts are shown in table 1.
A 90% overall correct classification of CIN2 and CIN3
was obtained with Cytokeratin 2 as the significant discri-
minatory factor. The CART analysis resulted in a 97%
correct classification using Cytokeratin 2 and actin alpha
as discriminating factors. Figure 4 shows a scatterplot
using these two proteins.
Cytokeratin 2 was identified with five peptides. An
MS2 spectrum for one of these peptides is shown in fig-
ure 5 panel A. Panel B in the figure show the y- and b-
series with the peptide sequence, and panel C a multi-
alignment of this part of the protein sequence with all
the other cytokeratins identified in this study. The
multi-alignment shows that this peptide makes Cytoker-
atin 2 (CK-2) different from the other cytokeratins
identified.
In a small preliminary immunohistochemical study, we
found that normal epithelial cells in the lower half are
CK-2 positive (but not the basal cells). CIN-3 lesions are
negative. CIN-2 lesions show CK-2 expression in the
low and middle part of the epithelium, but the cells are
not as strongly positive as the normal epithelium, and in
a patchy manner (figure 6).
Discussion
This study shows that CIN biopsies shed a complex
mixture of proteins into a cell culture medium for 24
hours at 4°C. Supernatants from 20 patient samples
were analyzed using a bottom-up shotgun proteomics
approach [21] in which the proteins were digested into
smaller peptides using trypsin. The peptide mixture was
then analyzed using uni-dimensional LC-MS/MS.
Despite the depletion of seven high abundance proteins
including immunoglobulins and albumin, peptides from
these proteins were detected, while transferrin was not
found at all after depletion. In addition, not unexpect-
edly haemoglobins constitute a relatively large part of
the identifications (cervical tissues with CIN2-3 are
usually richly vascularised) and should be included in
future depletion work. The protein mixtures still are of
such complexity after depletion that it would be
Table 1 Classification table showing the results from the
binary logistic regression model
Predicted
Group
Observed CIN2 CIN3 Percentage Correct
Step 1 Group CIN2 16 4 80.0
CIN3 0 20 100.0
Overall Percentage 90.0
A cut-value of 0.250 was used.
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processes.
Figure 3 A bar diagram showing the number of proteins covering other biological processes related to cell development and host-
virus interactions.
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ple using two-dimensional separations like 2D gels or
MudPit [22]. Selective enrichments of for example phos-
phorylated kinases that are important components in
regulation of the cell cycle [23] would reduce the com-
plexity of the samples while at the same time enrich
interesting proteins. The glycosylation pattern of pro-
teins is another interesting topic [24,25] that could be
further elucidated using this sample set.
The gene ontology bar diagram in figure 2 shows that
33% of the proteins identified are annotated to meta-
bolic processes, 35% to signal transduction in CIN2 and
27% in CIN3, 9% annotated to cell cycle processes in
CIN2 and 15% in CIN3, and annotated to trafficking/
transport. In agreement with our results, Panicker et al
[26] reported that 33% of the identified proteins in cer-
vical mucus samples were related to metabolism, while
Dasari et al [27] reported 32% after analysis of cervical-
vaginal fluid. The fraction of the proteins involved in
signal transduction processes (35 and 27%) in this study
is much higher than the results from the studies by
Panicker et al [26] and Dasari et al [27], who reported
1% and 3%, respectively. This may be due to the higher
efficiency of the exudation process of a biopsy (which in
principle has a much larger direct stroma contact sur-
face with the RPMI than intact cervical epithelium has
with cervical mucus or vaginal fluid) and the long incu-
bation time we have used (24 hours).
Several of the proteins found in this study have been
reported by others in cervical mucus samples [26], and
also in plasma samples from patients with CIN [28] or
in cervical tissue samples [29-32]. Vimentin was found
down-regulated in vaginal and cervical carcinoma
compared to normal tissue [31,32]. Actin, transthyretin,
lamin a/c, fibrinogen and apolipoprotein A-I are all pro-
teins identified in one or more of the mentioned studies,
and several of these proteins have been connected to
cancer or used as cancer markers [33-35]. Transthyretin
has been used as a biomarker for nutritional status and
inflammation, but post-translational modified forms
have also been reported as part of a biomarker panel for
early detection of ovarian cancer [36,37]. Transthyretin
was found in 6 of the 10 CIN3 samples and none of the
CIN2 samples. Alpha-1-acid glycoprotein (AGP) is
known to increase during acute-phase response, [38],
and has also been identified in other studies [26,27]
using cervical vaginal fluid or mucus. The heat shock
proteins are involved in a range of cell processes. They
are induced under stress conditions and known to be
over-expressed in human cancers. Some of them are
used as biomarkers for carcinogenesis and some as sig-
nals for aggressiveness of some cancers [39]. Two stu-
dies [30,31] found the level of heat shock protein 1
(Hsp27) to be up-regulated in carcinoma samples. How-
ever, another study discovered a decline [29] and related
this to the presence of HPV oncoproteins with a nega-
tive effect on the ability of lesions to undergo terminal
differentiation. We found no significant difference
between CIN2 and CIN3 samples with regards to Hsp27
based on spectral count comparison.
A conserved 7 amino acid sequence found in lipoca-
lins, including the lipocalin-type prostaglandin D
synthase (L-PGDS) was identified in 17 of the 20 sam-
ples in this study and was recently demonstrated to
modulate cell survival [40]. Lipocalins are normally pre-
sent at low concentrations, but the expression can
increase due to physiological conditions [40]. The tumor
suppressor p53 has been found to suppress the expres-
sion of L-PGDS [41]. A decrease in the p53 level, as
found in most CIN2-3 lesions [4], combined with a local
inflammation, might explain the frequent occurrence of
L-PGDS in the CIN samples.
Proteins from the intermediate filament (IF) protein
family is highly represented among the proteins identi-
fied in both the CIN2 and CIN3 group. The cytokeratins
belong to the type I and II of the IF’s, desmin and
vimentin belong to the type III and lamin to type V.
This group of proteins have been widely used as mar-
kers of different cancers [42].
Special attention should be paid to the late epithelial
cell differentiation marker Cytokeratin 2 (CK-2), which
was found to have highest discriminatory power
between CIN2 and CIN3, with 90% correct classifica-
tion. The protein was identified using 5 different pep-
tides (2 unique), and only in samples from the CIN2
group (in 8 of the 10 samples).
Figure 4 Scatterplot showing the discrimination between CIN2
and CIN3 using cytokeratin 2 and actin alpha.
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process in the uppermost epidermal layers of the normal
skin [43], and has normally been associated with the
skin disorder ichthyosis bullosa of Siemens [44]. The
protein was characterized by Collin et al [45,46], and
was found overexpressed in patients with head and neck
squamous cell cancer [47]. The fact that CK-2 is identi-
fied in CIN-2 lesions only indicates that the epithelial
cells have a greater tendency to high-end differentiation
than CIN3 lesions, which is biologically well under-
standable. To our knowledge, this is the first report of
Cytokeratin 2 associated with differences between CIN2
and CIN3, or with other neoplasia [48].
Although the number of samples is small, the proteo-
mics results have been confirmed by immunohistochem-
ical evaluation, when performed, and further validation
is in progress.
A differentiation between a CIN2 and CIN3 diagnosis
has at the moment no consequence for patients with
regards to follow-up or treatment as all these patients in
principle will undergo surgical cone excision. However,
t h ef a c tt h a tt h e r ea r ed i f f e r e n c e sa tt h ep r o t e i nl e v e l
amongst high grade CIN lesions with microscopically
different epithelial appearances, as detectable by expert
pathologists supported by p16 and MIB-1 immunohisto-
chemistry, make clear that these differences are real and
may have biological impact. These additional novel mar-
kers could help pathologists in differentiating CIN2 and
CIN3. This may be especially of interest as high grade
CIN 3 lesions have a lower likelihood to regress sponta-
n e o u s l ya n dah i g h e rp r o b a b i l i t yt op r o g r e s st oi n v a s i v e
cancer, than CIN 2 lesions [3]. The fact that this well-
known knowledge currently is not used in therapeutic
decision making, is due to the lack of reproducibility
amongst pathologists when classifying CIN 2 and CIN3
lesion with conventional Hematoxyllin and Eosin stained
sections alone. However, with the advent of new mole-
cular immunohistochemical biomarkers, and possibly
Figure 5 MS2 spectrum of the peptide with the sequence VDLLNQEIEFLK (A), the sequence with the y- and b-series shown (B) and
the part of the sequence containing this peptide shown in a multialignment of all identified cytokeratins.
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ble strategy as described in the current study, the dis-
tinction could become of clinical interest.
Conclusions
The current study led to identify 114 proteins, including
several ones that had been previously identified by
others [26,27,29-32]. The late epithelial cell differentia-
tion marker Cytokeratin 2 was found to have the highest
discriminatory power between CIN2 and CIN3, with
90% correct classification, thus suggesting a role for
Cytokeratin 2 as a grading marker in CIN. As a whole,
the study highlights the informative potential in terms
of either biologic knowledge or diagnostic refinement
that is inherent in a proteomic analysis of cancer
supernatants.
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